GO:0036046 protein demalonylation: Mechanism, Genes, Functions

Protein demalonylation (GO:0036046) is a biological process defined as the removal of a malonyl group (CO-CH2-CO) from an amino acid residue within a protein or peptide. This reversible post-translational modification is emerging as a critical regulatory layer in mitochondrial and cellular metabolism, with SIRT5 being the best-characterized enzyme responsible for this activity in mammals. The malonyl group is a three-carbon dicarboxylic acyl moiety derived from malonyl-CoA, and its covalent attachment to lysine residues can influence protein function, stability, and interactions. Understanding demalonylation is essential because it directly opposes malonylation, a modification associated with metabolic stress and disease states. The importance of protein demalonylation extends across multiple physiological contexts. In the heart, SIRT5-mediated demalonylation of GSTP1 protects cardiomyocytes from pyroptosis under diabetic conditions. In innate immunity, demalonylation of DDX3 by SIRT5 enhances antiviral responses. In cancer, SIRT5 contributes to colorectal carcinogenesis by modulating glutaminolysis through deglutarylation, a related deacylase activity. These findings position demalonylation as a key node connecting mitochondrial metabolism, cellular stress responses, and disease pathogenesis. For researchers, GO:0036046 provides a framework to investigate how dynamic changes in protein malonylation status affect cellular physiology. The process is enzymatically controlled, substrate-specific, and responsive to metabolic cues, making it an attractive target for therapeutic intervention and biomarker discovery. This article synthesizes current knowledge on the mechanisms, key genes, disease relevance, and research methods for studying protein demalonylation, with a focus on CRISPR-based functional genomics approaches.

Protein demalonylation (GO:0036046) is the enzymatic removal of a malonyl group (CO-CH2-CO) from an amino acid residue within a protein or peptide. This process reverses protein malonylation, a post-translational modification where a malonyl group is covalently attached to a lysine residue. Demalonylation is catalyzed by specific deacylase enzymes, most notably sirtuin 5 (SIRT5), which can remove malonyl, succinyl, and glutaryl groups from target proteins. The reaction restores the unmodified amino acid side chain, thereby altering the protein's charge, structure, and functional properties.

Protein demalonylation is important because it dynamically regulates protein function in response to metabolic and stress signals, and its dysregulation is linked to major human diseases including cancer, cardiovascular disorders, and immune dysfunction. As the enzymatic counterpart to malonylation, demalonylation provides a reversible switch that cells use to fine-tune mitochondrial metabolism, stress responses, and cell survival. Understanding this process offers opportunities for therapeutic targeting of SIRT5 and related enzymes, as well as for developing biomarkers of metabolic disease.

The following genes and proteins are central to the study of protein demalonylation, either as enzymes, substrates, or regulatory components.

Protein demalonylation is regulated at multiple levels. The availability of NAD+ directly controls SIRT5 activity, linking demalonylation to cellular energy status and redox balance. NAMPT, a key enzyme in NAD+ salvage, influences SIRT5 function by maintaining NAD+ pools. Metabolic cues such as nutrient availability and mitochondrial stress can alter SIRT5 expression and activity. Additionally, the balance between malonylation and demalonylation is influenced by malonyl-CoA levels, which reflect fatty acid synthesis and oxidation. Post-translational modifications of SIRT5 itself and protein-protein interactions may also modulate its demalonylase activity. In cancer, SIRT5 expression is often dysregulated, contributing to metabolic reprogramming and tumor progression.

SIRT5-mediated demalonylation of GSTP1 suppresses cardiomyocyte pyroptosis in diabetic cardiomyopathy. This suggests that enhancing demalonylation could be cardioprotective under diabetic conditions. The malonylation-demalonylation balance may serve as a therapeutic target for diabetic heart disease.

SIRT5 contributes to colorectal carcinogenesis by enhancing glutaminolysis in a deglutarylation-dependent manner. Although this involves deglutarylation rather than demalonylation, the shared enzymatic machinery and substrate overlap highlight the broader role of SIRT5 in cancer metabolism. Targeting SIRT5 activity may disrupt metabolic dependencies in colorectal cancer.

Demalonylation of DDX3 by SIRT5 promotes antiviral innate immune responses. This identifies demalonylation as a positive regulator of host defense. Modulating SIRT5 activity could potentially enhance antiviral immunity, though further studies are needed.

Mitochondrial sirtuins, including SIRT5, are important modulators of mitochondrial energy metabolism and are implicated in stem cell function and cancer. Dysregulated demalonylation may contribute to metabolic syndrome, neurodegeneration, and aging-related decline. Understanding these links could inform therapeutic strategies targeting sirtuin pathways.

Mass spectrometry-based proteomics is the primary method for identifying malonylated lysine residues and quantifying demalonylation. Enrichment of malonylated peptides using anti-malonyl-lysine antibodies followed by LC-MS/MS allows site-specific mapping. Comparative proteomics between wild-type and SIRT5 knockout cells can reveal substrate specificity.

In vitro demalonylation assays using recombinant SIRT5 and malonylated substrate peptides or proteins can directly measure enzymatic activity. These assays typically monitor NAD+ consumption or the release of the malonyl group. Such methods are essential for validating candidate substrates and testing inhibitors.

CRISPR-Cas9 knockout of SIRT5 or substrate genes, combined with overexpression or point mutations, enables functional dissection of demalonylation pathways. Phenotypic readouts include cell viability, pyroptosis, antiviral responses, and metabolic flux. These approaches are critical for linking demalonylation to disease phenotypes.

Fluorescence microscopy with tagged proteins can reveal how demalonylation affects subcellular localization. For example, DDX3 localization changes upon SIRT5-mediated demalonylation can be tracked using GFP fusions. Live-cell imaging of NAD+ dynamics may also provide insights into SIRT5 activity.

Researchers studying protein demalonylation-related genes often need to determine whether a candidate gene is causally involved in a specific phenotype, such as metabolic reprogramming, immune regulation, or cell death. Establishing causality requires precise genetic tools that can knockout, mutate, tag, or overexpress the gene of interest in relevant cell models. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research.

Protein demalonylation (GO:0036046) is a fundamental post-translational regulatory process mediated primarily by SIRT5, with critical roles in metabolism, immunity, and disease. The reversible nature of this modification allows cells to dynamically respond to metabolic and stress signals, and its dysregulation is implicated in diabetic cardiomyopathy, colorectal cancer, and antiviral immunity. Continued research using advanced CRISPR models and proteomic technologies will further elucidate the substrate landscape and therapeutic potential of targeting demalonylation pathways. As the field progresses, integrating genetic, biochemical, and computational approaches will be essential to translate demalonylation research into clinical applications. EDITGENE's suite of CRISPR services provides researchers with the tools needed to accelerate these discoveries.